5.90 (-%)
As of Nov 21, 2024
Source:
Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (“ABC”) Platform, for retinal medicines. Our goal is to prevent and treat the major causes of blindness by developing and commercializing next-generation therapeutics to address multiple unmet needs on the spectrum of retinal diseases.
| Country | United States |
| Headquarters | palo alto, california |
| Phone Number | (650) 281-0850 |
| Industry | manufacturing |
| CEO | Victor Perlroth |
| Website | kodiak.com |